mRNA-1273.214 Vaccine for Infant COVID-19 (BabyCOVE Trial)

"This medical research is seeking participants who are between 2 and 6 months of age."

"Currently, this trial is welcoming participants from 8 separate medical centres. These locations include Doral, Syracuse and Richmond as well as other sites across the nation. To reduce travel difficulties for enrollees, it may be beneficial to choose a facility located nearby."

"This medical trial is registering 700 infants aged between two months and six months, who have contracted covid-19. For eligibility in this study, participants must be 12 weeks of age or older but under 6 months at the time of initial dose administration. Applicants should additionally have been born with a gestational period that was 37+ weeks (for Part 1) or 34+ for Part 2 and their birth weight had to exceed 2.5 kilograms without any signs of fetal growth restriction. In addition, it's mandatory for parents/guardians to comprehend the protocol mandated follow up procedures as well as sign an informed consent form prior to enrollment."

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, first published on September 30th 2022, is presently enrolling participants. There is a requirement for 700 patients to be recruited from 8 distinct medical facilities."

"As this is a Phase 2 trial, with some data supporting safety but no efficacy evidence yet, our team at Power have rated Part 1: mRNA-1273.214 Dose B as having an inherent safety of 2 on the scale from 1 to 3."

"Affirmative, the data from clinicaltrials.gov reveals that this medical experiment is actively recruiting volunteers. The trial was made available to the public on September 30th 2022 and was last revised on October 21st 2022. In total, 700 participants need to be recruited across 8 different sites."